Tenpoint Therapeutics and Visus Therapeutics have completed their merger "to create an entirely new chapter in ophthalmic therapeutic medications aimed at rejuvenating the aging eye," according to a joint press release from the companies. The merger unites a syndicate of institutional investors committed to advancing BRIMOCHOL PF, Tenpoint's once-daily presbyopia-correcting eyedrop, through marketing approval to patients worldwide while further advancing Tenpoint’s pipeline into clinical development.

Tenpoint reports that it will file a New Drug Application with the FDA for BRIMOCHOL PF with the goal of a US launch in the first half of 2026. In addition to BRIMOCHOL, Tenpoint's pipeline is comprised of TPT-161, a novel small molecule designed to reverse cataract formation in aging adults, and TPT-005, a cell therapy targeting RPE cell replacement for geographic atrophy.

To support the continued development of these programs, Tenpoint said it will soon embark on a crossover financing round with insider participation. 

With the combined teams of Tenpoint and Visus, "we have the right expertise to develop and successfully launch innovative products with the potential to be first and best in class in ophthalmic medicines,” said Henric Bjarke, chief executive officer of the newly merged company.